Stock Price Prediction

JMP Securities maintains a bullish view on Rallybio (RLYB) with a price target of $7.00, citing its promising clinical pipeline, particularly the advancement of RLYB212 into Phase 2 trials in 2025. Analysts highlight the de-risking safety data and comprehensive natural history studies as key drivers for future growth. The stock's current focus on rare disease therapies positions it well for long-term value creation.

Rallybio (RLYB) faces bearish sentiment due to its narrow drug pipeline and financial challenges. The stock, currently trading below $2, has a price target of $5-$7, but its cash burn and long development timelines for key drugs like RLYB212 increase risks. Without near-term catalysts, the stock may struggle to gain momentum.